Metraipolis › archive › dc_a526cd4566a2

CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41375077
DOI
10.3390/cancers17233876
License (as archived)
solo-consultazione
Archived
2026-11-07T23:24:33.261Z
SHA-256 of the archived text
541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c
Stable URL of this page
https://metraipolis.com/documento/dc_a526cd4566a2

How to cite

CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077 — Europe PMC (en), https://europepmc.org/article/MED/41375077 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a526cd4566a2 (Metraipolis archive dc_a526cd4566a2, sha256 541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c)
BibTeX
@misc{dca526cd4566a2,
  title = {CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer — Europe PMC PMID:41375077},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41375077},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a526cd4566a2; sha256 541bb8811a9808117f8e98a6a64cb149d5bec48a941bf58eeb699505d977945c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41375077. Agents can read the archived copy with the MCP tool read_document.